Prognosis of critically ill cirrhotic versus non-cirrhotic patients: a comprehensive score-matched study

BMC Anesthesiology

Table 2 APACHE III-matched patient demographic data and clinical characteristics according to cirrhosis and non-cirrhosis

	Total (n = 174)	Cirrhosis (n = 87)	Non-cirrhosis (n = 87)	p-value
Age (years)	65.5 ± 1.1	59.8 ± 1.5	71.3 ± 1.4	<0.001
Male/Female	123/51	64/23	59/28	NS(0.405)
Length of ICU stay (days)	14 ± 1	11 ± 1	16 ± 2	0.009
Length of Hospital stay (days)	32 ± 2	30 ± 3	35 ± 3	NS(0.223)
Body weight on ICU admission (kg)	61 ± 1.0	65 ± 1	57 ± 1	<0.001
GCS, ICU first day (points)	9 ± 0	10 ± 1	9 ± 1	NS(0.077)
MAP, ICU admission (mmHg)	78 ± 1	80 ± 2	76 ± 2	NS(0.137)
Serum Creatinine, ICU first day (mg/dl)	2.5 ± 0.2	2.4 ± 0.2	2.5 ± 0.3	NS(0.885)
Arterial HCO₃ ⁻, ICU first day	21 ± 1	19 ± 1.0	22 ± 1.0	0.002
Serum Sodium, ICU first day (mg/dl)	138 ± 1.0	138 ± 1.0	138 ± 1.0	NS(0.890)
Bilirubin, ICU first day (mg/dl)	6.4 ± 0.7	11.4 ± 1.3	1.4 ± 0.3	<0.001
Albumin, ICU first day (g/l)	2.4 ± 0.1	2.4 ± 0.1	2.4 ± 0.1	NS(0.329)
Blood Sugar, ICU first day (mg/dl)	166 ± 7	159 ± 11	170 ± 10.0	NS(0.482)
Hemoglobin, ICU first day (g/dl)	9.6 ± 0.2	9.2 ± 0.2	10.0 ± 0.2	0.024
Platelets, ICU first day (×10³/μL)	145.0 ± 9.1	79.4 ± 5.9	210.5 ± 14.1	<0.001
Leukocytes, ICU first day (×10³/μL)	14.5 ± 0.7	13.5 ± 1.0	15.5 ± 0.8	NS(0.133)
PaO₂/FiO₂, ICU first day(mmHg)	268 ± 11	275 ± 13	262 ± 17	NS(0.536)
Shock(%)	54 (31.0)	21 (24.1)	33 (37.9)	0.049
Hospital mortality (%)	114 (65.5)	64 (73.6)	50 (57.5)	0.026
Score systems
APACHE III, ICU first day(mean ± SE)	87.8 ± 2.1	87.7 ± 3.4	88.0 ± 2.5	NS(0.941)
SOFA, ICU first day(mean ± SE)	9.6 ± 0.3	11.3 ± 0.4	8.0 ± 0.3	<0.001
RIFLE, ICU first day(mean ± SE)	1.6 ± 0.1	1.6 ± 0.1	1.7 ± 0.2	NS(0.913)

Abbreviation: NS, not significant; ICU, intensive care unit; SE, standard error; GCS, Glasgow coma scale; MAP, mean arterial pressure; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, sequential organ failure assessment; RIFLE, risk of renal failure, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage renal failure.

ISSN: 1471-2253